CBD probably reduces seizures in children with drug-resistant epilepsy, systematic review confirms

High-quality RCTs show cannabidiol reduces monthly seizure frequency by about 20% compared to placebo in children with drug-resistant epilepsy, though it does not significantly increase seizure freedom rates.

Elliott, Jesse et al.·Epilepsia·2019·Strong EvidenceSystematic Review
RTHC-02023Systematic ReviewStrong Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

CBD reduced median monthly seizure frequency by 19.8% vs placebo (95% CI: -27.0% to -12.6%) and increased the proportion achieving 50%+ seizure reduction (RR = 1.76). However, seizure freedom was not significantly different. Diarrhea was significantly more common with CBD (RR = 2.25).

Key Numbers

4 RCTs + 19 non-randomized studies. Seizure frequency reduction: -19.8% (95% CI: -27.0% to -12.6%). 50%+ seizure reduction: RR 1.76 (95% CI: 1.07-2.88). Diarrhea: RR 2.25 (95% CI: 1.38-3.68). No significant difference in seizure freedom, quality of life, or sleep.

How They Did This

Living systematic review with meta-analysis of 4 RCTs and 19 non-randomized studies. Searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature. Risk of bias assessed per study; GRADE used for quality of evidence per outcome.

Why This Research Matters

This provides the most rigorous assessment of CBD for pediatric epilepsy at the time of publication. The moderate-certainty evidence supports its use for drug-resistant cases, while clearly noting that results apply specifically to pharmaceutical-grade CBD, not all cannabis products.

The Bigger Picture

This review arrived as CBD products were flooding consumer markets with epilepsy claims. The evidence specifically supports pharmaceutical-grade cannabidiol for specific severe epilepsies, not broad use of unregulated CBD products for seizure disorders.

What This Study Doesn't Tell Us

All non-randomized studies were at high risk of bias. Evidence is primarily limited to pharmaceutical-grade CBD. Quality of life and sleep outcomes showed no significant improvement. Short follow-up periods in most studies.

Questions This Raises

  • ?Would longer treatment periods show improvements in quality of life and sleep?
  • ?Does CBD work for epilepsy types beyond Dravet and Lennox-Gastaut syndromes?
  • ?How much of the seizure benefit is attributable to CBD's interaction with clobazam rather than direct effects?

Trust & Context

Key Stat:
CBD reduced monthly seizures by 19.8% vs placebo in drug-resistant pediatric epilepsy
Evidence Grade:
Strong: systematic review with meta-analysis including 4 low-risk-of-bias RCTs and GRADE quality assessment.
Study Age:
Published in 2019.
Original Title:
Cannabis-based products for pediatric epilepsy: A systematic review.
Published In:
Epilepsia, 60(1), 6-19 (2019)
Database ID:
RTHC-02023

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does CBD help children with epilepsy?

Pharmaceutical-grade CBD reduced monthly seizure frequency by about 20% compared to placebo in children with drug-resistant epilepsy, based on high-quality clinical trial data. It did not achieve complete seizure freedom.

Can any CBD product be used for epilepsy?

The evidence specifically supports pharmaceutical-grade cannabidiol (like Epidiolex). The authors explicitly warn against extending these findings to all cannabis-based products, which vary widely in composition and quality.

Read More on RethinkTHC

Cite This Study

RTHC-02023·https://rethinkthc.com/research/RTHC-02023

APA

Elliott, Jesse; DeJean, Deirdre; Clifford, Tammy; Coyle, Doug; Potter, Beth K; Skidmore, Becky; Alexander, Christine; Repetski, Alexander E; Shukla, Vijay; McCoy, Bláthnaid; Wells, George A. (2019). Cannabis-based products for pediatric epilepsy: A systematic review.. Epilepsia, 60(1), 6-19. https://doi.org/10.1111/epi.14608

MLA

Elliott, Jesse, et al. "Cannabis-based products for pediatric epilepsy: A systematic review.." Epilepsia, 2019. https://doi.org/10.1111/epi.14608

RethinkTHC

RethinkTHC Research Database. "Cannabis-based products for pediatric epilepsy: A systematic..." RTHC-02023. Retrieved from https://rethinkthc.com/research/elliott-2019-cannabisbased-products-for-pediatric

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.